Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era
Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era
复制标题
DOI：
10.3109/10428194.2010.522285
复制
发表时间：
2010-11-01
影响因子：
2.6
通讯作者：
Tamaru, Jun-Ichi
中科院分区：
文献类型：
--
作者：
Hanzawa, Kyoko;Momose, Shuji;Tamaru, Jun-Ichi
YB-1的表达已被报道在许多人类恶性肿瘤中预测不良的临床结果，包括血液系统恶性肿瘤。在本研究中，我们研究了单一机构中弥漫性大B细胞淋巴瘤(DLBCL)患者YB-1的表达与临床病理特征的相关性。应用免疫组织化学方法检测168例鼻咽癌组织中YB-1的表达。168例中15例(8.9%)有YB-1胞浆表达。YB-1的表达与5年总生存期(OS)显著相关(p=0.023)。利妥昔单抗加CHOP疗法(n=94)提高了YB-1阳性和阴性患者的5年生存率。综上所述，本报告提供的数据表明，YB-1胞浆表达是CHOP治疗DLBCL预后较差的因素，而利妥昔单抗提高了YB-1阳性和阴性DLBCL患者的存活率。
The expression of YB-1 has been reported to predict poor clinical outcome in many human malignancies, including hematopoietic malignancies. In this study, we investigated the correlations between YB-1 expression and the clinicopathological features of patients with diffuse large B-cell lymphoma (DLBCL) in a single institution. The expression of YB-1 was analyzed in 168 cases by immunohistochemistry. Fifteen out of 168 cases (8.9%) showed cytoplasmic expression of YB-1. The expression of YB-1 was significantly associated with 5-year overall survival (OS) (p = 0.023). Rituximab plus CHOP therapy (n = 94) improved the 5-year survival rate in both YB-1-positive and -negative patients. In conclusion, the data presented in this report provide evidence that the cytoplasmic expression of YB-1 is a poor prognosis factor in DLBCL treated with CHOP therapy, whereas rituximab improves the survival of both YB-1-positive and -negative patients with DLBCL.